Arhalofenate: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 239 patients with gout, hyperuricemia and a history of >=3 flares in the last 12 months showed that 800 mg once-daily oral arhalofenate met the primary endpoint of reducing flare rate at week 12 vs. 300 mg once-daily allopurinol (0.66 vs. 1.24, p=0.0056). Additionally, 800 mg arhalofenate reduced flare rate at week 12 by 41% vs. placebo, which had a flare rate of 1.13 (p=0.049). At week 12, a 600 mg dose of once-daily arhalofenate led to a flare rate of 1.04, and allopurinol plus 0.6 mg colchicine led to a flare rate of 0.40. ...